Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2-Reference-Cited by-同舟云学术

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Published:2017-06-13 Issue:2 Volume:362 Page:338-346
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Busch-Petersen Jakob,Carpenter Donald C.,Burman Miriam,Foley James,Hunsberger Gerald E.,Kilian David J.,Salmon Michael,Mayer Ruth J.,Yonchuk John G.,Tal-Singer Ruth

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits

2. LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2

3. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases;Busch-Petersen;Curr Top Med Chem,2006

4. Busch-Petersen J inventor and assignee (2007) Preparation of N-sulfonylphenyl-N′-(hetero)arylureas as antagonists of chemokines, interleukin-8 (IL-8). U.S. patent 20,070,249,672A1. 2007 Oct 25.

5. CXCR2 antagonists for the treatment of pulmonary disease

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1;ChemMedChem;2024-07-24

2. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”;mBio;2024-05-08

3. Neutrophil Extracellular Traps in Cardiovascular and Aortic Disease: A Narrative Review on Molecular Mechanisms and Therapeutic Targeting;International Journal of Molecular Sciences;2024-04-03

4. Inhibition of chemokine receptor CXCR2 attenuates postoperative peritoneal adhesion formation;Surgery;2024-04

5. Pharmacologically targeting intracellular allosteric sites of GPCRs for drug discovery;Drug Discovery Today;2023-12